News

See the latest news about TARA, press releases, videos, and events. We're active in the drug discovery and cardiac toxicology communities, so keep an eye out for conferences we're attending.

VantAI and TARA Biosystems Partner to Discover New Medicines

NEW YORK, NY - (EurekAlert) - VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARA’s state-of-the-art in vitro human …

READ MORE

TARA Biosystems Report Study Results Demonstrating In Vitro Cardiac Biology Model Mimics Human Drug Response

NEW YORK, NY - (EurekAlert) - TARA Biosystems today reported study results demonstrating the ability of TARA’s in vitro human cardiac models to reproduce drug responses similar to those observed in humans. Appearing …

READ MORE

TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilities

NEW YORK, NY - (BUSINESS WIRE) - TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 …

READ MORE

TARA Biosystems Presents Translational Disease Models at Keystone Heart Failure Symposium

Tuesday March 3, 2020 – Keystone, Colorado.  TARA Biosystems Inc. today reported data showcasing its Biowire™ II as a platform for heart failure drug discovery.  Speaking at this year's Keystone

READ MORE

Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development

NEW YORK, NY - (Newswire.com) - TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a

READ MORE

TARA Biosystems Launches Cardiotype.Ca™ Cardiac Calcium Signaling Assay: In Vitro Assay Accelerates Drug Development in Human-Relevant Heart Models

​​ TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s <…

READ MORE

Heart-on-a-Chip Mimics Drug Response Seen in Humans: In Vitro Approach Provides Predictive Platform for Human-Based Drug Discovery

NEW YORK, N.Y. (Newswire.com)— Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The

READ MORE

TARA Secures Exclusive Worldwide License to Columbia University Intellectual Property relating to Engineered Human Cardiac Tissues

NEW YORK, N.Y. (Newswire.com)— TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia …

READ MORE

TARA Announces Issuance of US Patent for Biowire™ II Platform

New York, NY, (Newswire.com) - TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has …

READ MORE

TARA presents at WuXi Healthcare Forum in Shanghai

TARA presents today at the WuXi Healthcare Forum in Shanghai.  The forum brings together 1000+ innovators, entrepreneurs, clinicians, and investors from around the world that are shaping the future of healthcare.

READ MORE